Manipulation? Maybe not? The below post, in a nutshell,

New Post Public Reply Private Reply Replies (4) Message Board
jconst345 HCIT #64927
970
Manipulation? Maybe not? The below post, in a nutshell, elaborates on my thought that there is NO manipulation, just retail traders doing their thing. That’s your “unknown enemy” that behaves so irrationally that you can’t possibly assign the least bit of logic to it which actually explains things perfectly.

Read further for my rationale:

-manipulators end goal is financial gain, who are the possibilities? Big pharma, financiers, traders

Big pharma: Takeover CYDY; Negotiate better partnership terms; Avoid revenue losses on existing/upcoming pipelines

Financiers: Better terms for next financing round; Lower conversion price on previous round

Traders: short term profits

Weapons available: Shorting the stock into oblivion. Selling existing shares accumulated in the past.

Risk: Stock rips in their face as the pockets of the collective investment community eventually overpowers theirs given possible high visibility and government (OWS) support. Life and death here, if we literally save lives, we won’t fly under the radar, the worlds eyes will be on us. Eventually the manipulator will need to dial it in.

Breaking it down further against manipulation:
Big pharma - NP won’t be doing anything until S/c is done or long haulers is done or HIV PDUFA outcome is known. Assuming any of those succeed, he won’t be selling the firm AND his negotiating position is worlds better regardless of stock price AND the jig is over for Big pharma losing revs, because they will. So if big pharma manipulation is basically futile, then who?

Financiers - let’s assume you need to be at least 1/3 of the volume to hold a stock down. This has been going on for weeks if not months. The amount of $$ to risk to do that likely exceeds any potential gain from a next round of financing at these prices. The potential for the stock to go vertical overnight on an EUA or OWS or approval announcement is high. I put low probability that Iliad or Paulson are keeping this down. They will do just fine if the stock rips, no need to potentially shoot their own foot.

Traders - we already saw this at $10. It worked. They made $$. But that was low hanging fruit. The fruit is not low hanging at $3 or $2. It just isn’t.

Yet despite the above, the stock keeps falling. What gives?

I’ll posit the following - 43,000 retail traders is what gives. They are the weakest hands out there. They whip this around, panic and hope and fear and greed and fast money and Robinhood and etc. They have thin pockets, 5,000 shares, 20,000 shares whatever it is per person. It adds up quickly when multiplied by 43,000. Cash strapped, trigger happy, unemployed possibly, whittling retirement accounts... they can make charts look crazy in both directions.

There are virtually no institutional holders here. It’s an OTC stock with just hopes and dreams right now. Institutional big money would much rather buy certainty than uncertainty. Hence the mystery billionaire saying they would personally step in ASSUMING APPROVAL. A billionaire can easily get involved at $10 or $15 per share with low risk than $2 per share with high risk (in their minds, not mine...).

So I take the no manipulation standpoint at this time as I just don’t see a successful endgame for any of the players given what we know about NP and the probability of the success of LL and the high visibility of Covid across the entire planet. I think it’s all retail.

You know what that does? It comforts the heck out of me as I wrap up my Lagavulin. Once smart $$ is locked in, the trend will permanently reverse.

Happy to have well thought out holes poked into the above.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 3

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 6

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 3

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 5

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Cut Winter Heating Costs with Townsend's Rebate Help

Updated Category News Views 4

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Continue Reading
China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 3

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 3

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 7

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 4

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Food Holdings Transforms Strategies for Future Growth

Updated Category News Views 235

Innovative Food Holdings Sets New Directions for Future Growth Innovative Food Holdings, Inc. (OTCQB: IVFH), based in Broadview, Illinois, isa prominent vendor of specialty gourmet foods targeted at professional chefs.The company recently indicated the timeline for its annual meeting of shareholdersand shared an insightful letter from its CEO, Robert W. (Bill)...

Continue Reading
LET Mining Introduces Innovative BTC Cloud Mining Contracts

Updated Category News Views 141

LET Mining Revolutionizes Passive Income with Cloud Mining Contracts Recently, the cryptocurrency world has witnessed a significant uptick in Bitcoin prices, reaffirming its status as the digital gold of our time. LET Mining, a leader in cloud mining solutions, has risen to the occasion by launching innovative BTC cloud mining contracts designed to turn Bitcoin holdings...

Continue Reading
Alvotech and Teva Move Forward with Proposed AVT06 Biosimilar

Updated Category News Views 229

Alvotech and Teva Collaborate on a New Biosimilar Alvotech (NASDAQ: ALVO), a pioneering biotech firm known for its innovative work in biosimilar medicines, partners with Teva Pharmaceuticals to announce a significant update regarding AVT06, their proposed biosimilar to the widely recognized Eylea (aflibercept). The recent acceptance of their Biologics License Application...

Continue Reading
C4 Therapeutics Strengthens Governance with New Incentive Amendments

Updated Category News Views 85

C4 Therapeutics Reinforces Shareholder Rights with New Amendments C4 Therapeutics, Inc. (NASDAQ:CCCC), a notable biotechnology company, has recently made impactful changes to its stock incentive plan. This amendment aims to improve corporate governance by preventing the lowering of exercise prices for stock options without obtaining prior approval from shareholders....

Continue Reading
ABM Reports Fourth Quarter Results and 2025 Financial Outlook

Updated Category News Views 326

ABM Reports Fourth Quarter and Full Fiscal Results ABM (NYSE: ABM), a recognized leader in facility solutions, recently shared its financial results for the fourth quarter and the complete fiscal year. In the fourth quarter, the company achieved remarkable revenues of $2.2 billion, showcasing an organic growth rate of 3.2%. This marks a significant turnaround and aligns...

Continue Reading